APLS

19.59

2.49% -0.50

Dopo l'orario di chiusura: 19.52 -0.07 -0.36%

Apellis Pharmaceuticals Inc (APLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché APLS Giù? Forum Previsione

Precedente Chiudi:

$20.09

Aprire:

$20.12

Volume 24 ore:

2.93M

Relative Volume:

1.23

Capitalizzazione di mercato:

$2.46B

Reddito:

$715.22M

Utile/perdita netta:

$-250.10M

Rapporto P/E:

-9.6502

EPS:

-2.03

Flusso di cassa netto:

$-205.58M

1 W Prestazione:

+0.62%

1M Prestazione:

+6.53%

6M Prestazione:

-34.70%

1 anno Prestazione:

-49.61%

Intervallo 1D:

$19.33

$20.30

Intervallo di 1 settimana:

$19.09

$20.32

Portata 52W:

$16.10

$41.94

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Nome

Apellis Pharmaceuticals Inc

Settore

Healthcare (1164)

Industria

Biotechnology (651)

Telefono

617-977-5700

Indirizzo

100 FIFTH AVENUE, WALTHAM, KY

Dipendente

710

Cinguettio

@ApellisPharma

Prossima data di guadagno

2024-12-05

Ultimi documenti SEC

APLS's Discussions on Twitter

Confronta APLS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
APLS Apellis Pharmaceuticals Inc	19.59	2.52B	715.22M	-250.10M	-205.58M	-2.03
VRTX Vertex Pharmaceuticals Inc	469.65	122.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	563.10	60.96B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.81	42.77B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.99	36.21B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	291.47	31.91B	3.81B	-644.79M	-669.77M	-6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-09	Downgrade	BofA Securities	Buy → Neutral
2025-05-09	Downgrade	Raymond James	Strong Buy → Outperform
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2024-12-17	Downgrade	Goldman	Buy → Neutral
2024-11-21	Iniziato	Morgan Stanley	Equal-Weight
2024-10-25	Iniziato	RBC Capital Mkts	Sector Perform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-10-16	Iniziato	William Blair	Outperform
2024-05-31	Iniziato	Piper Sandler	Neutral
2024-02-05	Aggiornamento	Jefferies	Hold → Buy
2023-12-14	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-11-09	Iniziato	Goldman	Buy
2023-11-02	Iniziato	Mizuho	Neutral
2023-10-06	Aggiornamento	JP Morgan	Neutral → Overweight
2023-09-15	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-08-29	Reiterato	Citigroup	Buy
2023-08-03	Downgrade	JP Morgan	Overweight → Neutral
2023-08-01	Downgrade	BofA Securities	Buy → Neutral
2023-01-03	Downgrade	Wells Fargo	Overweight → Equal Weight
2022-11-10	Downgrade	Jefferies	Buy → Hold
2022-07-19	Iniziato	H.C. Wainwright	Buy
2022-06-17	Ripresa	Stifel	Buy
2022-04-14	Downgrade	ROTH Capital	Neutral → Sell
2021-12-08	Iniziato	Wells Fargo	Overweight
2021-11-29	Downgrade	ROTH Capital	Buy → Neutral
2021-09-10	Reiterato	BMO Capital Markets	Outperform
2021-09-10	Reiterato	Credit Suisse	Neutral
2021-09-10	Reiterato	Needham	Buy
2021-09-10	Reiterato	Oppenheimer	Outperform
2021-09-10	Downgrade	Wedbush	Outperform → Neutral
2021-08-19	Iniziato	Jefferies	Buy
2021-08-19	Aggiornamento	Wedbush	Neutral → Outperform
2021-05-21	Iniziato	UBS	Buy
2021-04-16	Iniziato	Goldman	Buy
2020-11-19	Iniziato	Needham	Buy
2020-09-01	Iniziato	Stifel	Buy
2020-07-20	Iniziato	ROTH Capital	Buy
2020-06-17	Iniziato	BTIG Research	Neutral
2020-04-01	Iniziato	Raymond James	Strong Buy
2020-03-31	Iniziato	BMO Capital Markets	Outperform
2020-03-11	Aggiornamento	Wedbush	Underperform → Neutral
2020-01-07	Iniziato	SVB Leerink	Mkt Perform
2019-12-19	Iniziato	BofA/Merrill	Buy
2019-11-22	Iniziato	Wedbush	Underperform
2019-11-05	Iniziato	Credit Suisse	Neutral
2019-08-01	Reiterato	Cantor Fitzgerald	Overweight
2019-07-12	Aggiornamento	JP Morgan	Neutral → Overweight
2019-03-29	Iniziato	Robert W. Baird	Outperform
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-07-30	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-05-24	Iniziato	Cantor Fitzgerald	Overweight
2018-04-12	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-02-08	Iniziato	B. Riley FBR, Inc.	Buy

Mostra tutto

Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie

06:24 AM

What analysts say about Apellis Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional

06:24 AM

Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus

Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times

Jul 24, 2025

Jul 23, 2025

Is Apellis Pharmaceuticals Inc. a good long term investmentDynamic investment growth - jammulinksnews.com

Jul 23, 2025

Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com

Jul 23, 2025

Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent

Jul 21, 2025

Jul 18, 2025

Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛

Jul 18, 2025

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

Jul 18, 2025

Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech

Jul 18, 2025

Jul 16, 2025

APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus

Jul 16, 2025

Jul 15, 2025

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times

Jul 15, 2025

Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan

Jul 15, 2025

Jul 14, 2025

H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada

Jul 14, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

Jul 14, 2025

Jul 11, 2025

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail

Jul 11, 2025

Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada

Jul 11, 2025

Jul 10, 2025

Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN

Jul 10, 2025

Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada

Jul 10, 2025

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail

Jul 10, 2025

Jul 08, 2025

16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey

Jul 08, 2025

Jul 07, 2025

Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - MSN

Jul 07, 2025

Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛

Jul 07, 2025

Jul 06, 2025

Apellis stock surges after Sobi $300 million royalty deal - MSN

Jul 06, 2025

Jul 05, 2025